US specialist investors underestimate Tresiba
A major investor conference in New York gave some interesting insight into how East Coast specialist investors view companies like Novo Nordisk, Sanofi and Eli Lilly, says a portfolio manager.
BY STEFAN SINGH KAILAY
Specialist investors on the US East Coast might be underestimating the potential of Novo Nordisk’s diabetes drug Tresiba, as they fail to pay heed to an important settlement between rivals Sanofi and Eli Lilly, says Claus Henrik Johansen, senior portfolio manager in Danske Capital.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
These companies will be affected by new Jardiance-data
For abonnenter
